AP26113 (also known as Brigatinib) is an investigated small molecule for targeted cancer therapy. It is a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal factor receptor (EGFR). It is mainly under investigation for its treatmentefficacy on non-small cell lung cancer (NSCLC) where ALK is activated and EGFP mutations frequently occur.
Q1: What's your MOQ? A:It depends on different products,we can accept sample order or provide free sample for your test.
Q2:How about delivery leadtime? A:Delivery lead time: About 3-5 days after payment confirmed. (Chinese holiday not included)
Q3: Is there a discount? A:Different quantity has different discount.
Q4:How to start orders or make payments? A:Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T, Western Union or Bitcoin.
Q5: How do you treat quality complaint? A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.
Q6. We don't know you at all, how can we trust you? A: You are always warm welcomed to visit us at any time.Before we start B2B, MIC has audited our company on-spot and approved our credit.Commitment is the No.1 Point of our Enterprise's Value.
Q7.Do you test all your goods before delivery? A:Yes, we have 100% test before delivery,International Authorized Third-Party Test for the products if you need are highly welcomed.
Audited Supplier 
){kind=link}